Four things to know:
1. Second-quarter sales of $4.1 million represented a 67.7 percent increase year over year, according to a news release. It is the highest quarterly revenue in the company’s history.
2. Aurora Spine received FDA clearance for several of its products, including the Dexa Solo-L spinal fusion system and its Zip implant for lumbar spinal stenosis.
3. The company saw a net loss of $160,000 in the second quarter.
4. Aurora Spine’s CEO, Trent Northcutt, said: “These results stem directly from the sales and marketing strategy we established during 2021 and the industry’s emergence from the pandemic. Our proprietary products continue to be utilized by surgeons and pain interventionalists and we are seeing adoption of our products from more doctors that have participated in our nationwide training sessions.”
